Nasus Pharma (NSRX) Short term Debt (2024)
Nasus Pharma (NSRX) posted Short term Debt of $1.8 million for Q4 2024.
Nasus Pharma (NSRX) Short term Debt (2024) Analysis & Trends
Nasus Pharma (NSRX) has reported Short term Debt for 1 consecutive years, with $1.8 million the latest figure, recorded in Q4 2024.
- Short term Debt for Q4 2024 came in at $1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $1.8 million (changed N/A YoY), and the FY2024 annual result was $1.8 million, changed N/A from the prior year.
- Short term Debt was $1.8 million for Q4 2024 at Nasus Pharma.
- Over five years, Short term Debt peaked at $1.8 million in Q4 2024 and troughed at $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.80 Mn |